Aducanumab, or Aduhelm, is the first new Alzheimer’s treatment in 18 years and the first to attack the disease process. But some prominent experts say there’s not enough evidence it can address cognitive symptoms.
Top Investments for 2025: A Focus on the S&P 500
As we move into 2025, the S&P 500 continues to be a cornerstone of investment strategies, offering insights into the U.S. stock market’s health. Following